Exclusive Lateral Flow Manufacturing Agreement with BioSure UK Limited
York, U.K. 23 July 2021: Abingdon Health plc (AIM: ABDX) (“Abingdon” or “the Company”), a leading international developer and manufacturer of high quality and effective rapid tests, today announces that it has signed an exclusive manufacturing agreement with BioSure Limited (“BioSure”), a UK company specialising in the provision of rapid in-vitro diagnostic testing solutions.
Under the terms of the exclusive agreement, Abingdon will manufacture BioSure’s own lateral flow tests in the field of COVID19. The contract manufacturing services will utilise lateral flow manufacturing facilities at Abingdon’s York and Doncaster sites.
Chris Yates, CEO of Abingdon Health, commented: ” We are delighted to be supporting BioSure and building on our long-term collaboration with the BioSure team. We are committed to supporting the deployment of these much needed lateral flow test to the UK and international markets.”
Brigette Bard, CEO of BioSURE, commented: “We are thrilled to be continuing to build our portfolio of products with Abingdon. BioSure is committed to delivering British developed tests to the global market and Abingdon are our ideal partner to manufacture our world-leading products.”
Enquiries:
Abingdon Health plc
Chris Yates
Chief Executive Officer
About Abingdon Health
Abingdon Health is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York, England.
